Not connected to GLP3Planner: GLP3Planner has no connection to “GLP3-B” capsules or any shop selling them through social media ads. We don't sell medication, supplements or peptides and never take orders. For an order or refund, contact the seller or your bank or card provider.

Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #split dosing Clear filter

Educational Content

View all →
Showing 5 of 5 articles
No articles found matching your search. Try a different term or view all articles.

Microdosing GLP-1 Side Effects: What the Dose-Response Data Shows

A pharmacokinetics-anchored look at microdosing GLP-1 side effects across semaglutide, tirzepatide, and retatrutide: what trial dose-response data tells us about lower-dose GI tolerability, and which class-level serious risks persist at every dose.

Can You Split Retatrutide Twice Weekly? Schedule + Evidence

A twice-weekly retatrutide split takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. The 6-day half-life is what makes that spacing logical. Here is the pharmacokinetic reasoning, the practical mechanics, and the honest evidence picture.

Split Dosing Semaglutide Twice Weekly: What the Label Says

Split dosing semaglutide twice weekly takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. Every semaglutide injection is FDA-approved for once-weekly dosing only, so this is off-label. Here is the pharmacokinetic reasoning, the pen-mechanics problem, and the evidence gap.

Microdosing GLP-1 Reddit: What the Community Actually Reports

A community synthesis of what Reddit threads actually report about GLP-1 microdosing: fewer side effects, the "just 10 lbs" cohort, off-label inflammation use, and where anecdote meets pharmacokinetics. Anecdotes, not medical advice.

What Is Microdosing GLP-1? Definition, Benefits, and Risks Explained

What microdosing GLP-1 actually means, how it differs from standard titration, what clinical evidence exists, and the risks of using sub-standard doses of semaglutide, tirzepatide, or retatrutide.